Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P, Viardot A, Soekler M, Keller U, Schmidt C, Truemper L, Mahlberg R, Marks R, Hoeffkes HG, Metzner B, Dierlamm J, Frickhofen N, Haenel M, Neubauer A, Kneba M, Merli F, Tucci A, de Nully Brown P, Federico M, Lengfelder E, di Rocco A, Trappe R, Rosenwald A, Berdel C, Maisenhoelder M, Shpilberg O, Amam J, Christofyllakis K, Hartmann F, Murawski N, Stilgenbauer S, Nickelsen M, Wulf G, Glass B, Schmitz N, Altmann B, Loeffler M, Pfreundschuh M; FLYER Trial Investigators; German Lymphoma Alliance. Poeschel V, et al. Among authors: christofyllakis k. Lancet. 2019 Dec 21;394(10216):2271-2281. doi: 10.1016/S0140-6736(19)33008-9. Lancet. 2019. PMID: 31868632 Clinical Trial.
Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potential.
Bewarder M, Held G, Thurner L, Stilgenbauer S, Smola S, Preuss KD, Carbon G, Bette B, Christofyllakis K, Bittenbring JT, Felbel A, Hasse A, Murawski N, Kaddu-Mulindwa D, Neumann F. Bewarder M, et al. Among authors: christofyllakis k. Cancer Immunol Immunother. 2020 Aug;69(8):1535-1548. doi: 10.1007/s00262-020-02564-1. Epub 2020 Apr 16. Cancer Immunol Immunother. 2020. PMID: 32300857 Free PMC article.
Insertion site of central venous catheter correlates with catheter-related infectious events in patients undergoing intensive chemotherapy.
Rixecker T, Lesan V, Ahlgrimm M, Thurner L, Bewarder M, Murawski N, Christofyllakis K, Altmeyer S, Bick A, Stilgenbauer S, Bittenbring JT, Kaddu-Mulindwa D. Rixecker T, et al. Among authors: christofyllakis k. Bone Marrow Transplant. 2021 Jan;56(1):195-201. doi: 10.1038/s41409-020-01003-0. Epub 2020 Jul 23. Bone Marrow Transplant. 2021. PMID: 32704092
Integration of the B-Cell Receptor Antigen Neurabin-I/SAMD14 Into an Antibody Format as New Therapeutic Approach for the Treatment of Primary CNS Lymphoma.
Bewarder M, Kiefer M, Moelle C, Goerens L, Stilgenbauer S, Christofyllakis K, Kaddu-Mulindwa D, Fadle N, Regitz E, Neumann F, Hoth M, Preuss KD, Pfreundschuh M, Thurner L. Bewarder M, et al. Among authors: christofyllakis k. Front Oncol. 2020 Nov 12;10:580364. doi: 10.3389/fonc.2020.580364. eCollection 2020. Front Oncol. 2020. PMID: 33282736 Free PMC article.
The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma Cells.
Bewarder M, Kiefer M, Will H, Olesch K, Moelle C, Stilgenbauer S, Christofyllakis K, Kaddu-Mulindwa D, Bittenbring JT, Fadle N, Regitz E, Kaschek L, Hoth M, Neumann F, Preuss KD, Pfreundschuh M, Thurner L. Bewarder M, et al. Among authors: christofyllakis k. Hemasphere. 2021 Jul 13;5(8):e620. doi: 10.1097/HS9.0000000000000620. eCollection 2021 Aug. Hemasphere. 2021. PMID: 34263144 Free PMC article.
Killer immunoglobulin-like receptor 2DS5 is associated with recovery from coronavirus disease 2019.
Lesan V, Bewarder M, Metz C, Becker A, Mang S, Regitz E, Thurner L, Neumann F, Kos I, Christofyllakis K, Danziger G, Stilgenbauer S, Bals R, Lepper PM, Kaddu-Mulindwa D, Rixecker T. Lesan V, et al. Among authors: christofyllakis k. Intensive Care Med Exp. 2021 Sep 3;9(1):45. doi: 10.1186/s40635-021-00409-4. Intensive Care Med Exp. 2021. PMID: 34476598 Free PMC article.
Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial.
Kaddu-Mulindwa D, Lesan V, Berdel C, Stilgenbauer S, Bewarder M, Thurner L, Witzens-Harig M, Viardot A, Soekler M, Keller U, Truemper L, Christofyllakis K, Fleser O, Bittenbring JT, Poeschel V, Held G, Jagoda P. Kaddu-Mulindwa D, et al. Among authors: christofyllakis k. Leuk Lymphoma. 2022 Feb;63(2):326-334. doi: 10.1080/10428194.2021.1975193. Epub 2021 Oct 20. Leuk Lymphoma. 2022. PMID: 34668817
Cost-effectiveness of precision cancer medicine-current challenges in the use of next generation sequencing for comprehensive tumour genomic profiling and the role of clinical utility frameworks (Review).
Christofyllakis K, Bittenbring JT, Thurner L, Ahlgrimm M, Stilgenbauer S, Bewarder M, Kaddu-Mulindwa D. Christofyllakis K, et al. Mol Clin Oncol. 2022 Jan;16(1):21. doi: 10.3892/mco.2021.2453. Epub 2021 Nov 25. Mol Clin Oncol. 2022. PMID: 34909199 Free PMC article. Review.
Advances in Lymphoma Molecular Diagnostics.
Kos IA, Thurner L, Bittenbring JT, Christofyllakis K, Kaddu-Mulindwa D. Kos IA, et al. Among authors: christofyllakis k. Diagnostics (Basel). 2021 Nov 23;11(12):2174. doi: 10.3390/diagnostics11122174. Diagnostics (Basel). 2021. PMID: 34943410 Free PMC article. Review.
29 results